Prescribing information



Cosentyx is indicated for the treatment of: moderate to severe plaque psoriasis (PsO) in adults, adolescents and children from the age of 6 years who are candidates for systemic therapy; active psoriatic arthritis in adult patients, alone or in combination with MTX, when the response to previous DMARD therapy has been inadequate; active ankylosing spondylitis in adults who have responded inadequately to conventional therapy; active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated CRP and/or MRI evidence in adults who have responded inadequately to NSAIDs.


Image showing the results confirm what has been previously observed in Phase 3 clinical trials and support the use of Cosentyx in plaque psoriasis for fast and sustained skin clearance with emphasis on Start confidently with Cosentyx


BADBIR is one of the world’s largest prospective registries for psoriasis, with over 160 hospital sites in the UK and ROI, evaluating the long-term safety and effectiveness of biologic treatments.5–7

Analysis using the BADBIR data showed that in the real-world, your psoriasis patients can achieve high levels of drug survival and skin clearance with Cosentyx.5,7

Image showing High levels of drug survival over 2 years in PsO patients, with or without PsA from an Analysis by the BADBIR group
Image showing High levels of skin clearance at years 1 and 2 from analysis by Novartis using BADBIR data

Watch now: a 2-minute summary of this data

This summary demonstrates how you can achieve long-lasting efficacy and high drug survival with Cosentyx in biologic-naïve patients over 2 years in the real world.5,7



Click here for Cosentyx®(secukinumab) prescribing information

Graphic showing skin clearance rates with Cosentyx were sustained up to 2 years with icons for 86.5% at 1 year and 85.5% at 2 years

Adapted from Bewley A et al. 2019.7


aPASI score of <3 reflects clear or almost clear skin, or a physician global assessment of 0–1.8
aPASI scores at 12 and 24 months were imputed using data recorded ±90 days of each time point. The fall in patient numbers between Years 1 and 2 reflects fewer patients being on treatment long enough to reach the 2-year time point.7

aPASI, absolute Psoriasis Area Severity Index; BADBIR, British Association of Dermatologists Biologic and Immunomodulators Register; CI, confidence interval; CRP, C-reactive protein; DMARD, disease-modifying anti-rheumatic drugs; HR, hazard ratio; MRI, magnetic resonance imaging; MTX, methotrexate; NSAIDs, non-steroidal anti-inflammatory drugs; PsA, psoriatic arthritis; ROI, Republic of Ireland.


  1. Bissonnette R, et al. J Eur Acad Dermatol Venereol 2018;32:1507–1514.     
  2. Langley RG, et al. NEJM 2014;371(4):326–338.     
  3. Thaci D, et al. J Am Acad Dermatol 2015;7(3):400–409.     
  4. Blauvelt A, et al. J Am Acad Dermatol 2017;76(1):60–69.     
  5. Yiu ZZN, et al. Br J Dermatol 2020; 2020;183(2):294–302.     
  6. BADBIR. Available at: [Accessed November 2021].     
  7. Bewley A, et al. Secukinumab 300 mg demonstrates high and sustained effectiveness in treating patients with moderate to severe plaque psoriasis: Real world evidence from the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR). Poster presented at: the 6thAnnual Practical Symposium; 8–11 August 2019; Beaver Creek, Colorado, USA.     
  8. Amatore F, et al. J Eur Acad Dermatol Venereol 2019;33:464–483.
Rate this content: 
No votes yet
UK | November 2021 | 158791

Ask Speakers


Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]